A Scotland Based Cost-Effectiveness Analysis Of Idelalisib (Zydelig®) In Combination With Rituximab For The Treatment Of Adults With Chronic Lymphocytic Leukaemia Cll)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.